# name
Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

# metadata.dc.contributor.author[].value
Soriano Zaragoza, Francesc X. (Francesc Xavier)

# metadata.dc.description.abstract[].value
Mutations in mitochondrial energy-producing genes lead to a heterogeneous group of untreatable disorders known as primary mitochondrial diseases (MD). Leigh syndrome (LS) is the most common pediatric MD and is characterized by progressive neuromuscular affectation and premature death. Here, we show that daily cannabidiol (CBD) administration significantly extends lifespan and ameliorates pathology in two LS mouse models, and improves cellular function in fibroblasts from LS patients. CBD delays motor decline and neurodegenerative signs, improves social deficits and breathing abnormalities, decreases thermally induced seizures, and improves neuropathology in affected brain regions. Mechanistically, we identify peroxisome proliferator-activated receptor gamma (PPARγ) as a key nuclear receptor mediating CBD’s beneficial effects, while also providing proof of dysregulated PPARγ expression and activity as a common feature in both mouse neurons and fibroblasts from LS patients. Taken together, our results provide the first evidence for CBD as a potential treatment for LS.

# metadata.dc.relation.ispartof[].value
Nature Communications, 2024, vol. 15, num.1, p. 1-21

# metadata.dc.source[].value
Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)

# metadata.dc.title[].value
Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models